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Abstract
Introduction—Older women with ovarian cancer (OC) are less likely to receive guideline 
concordant treatment. Differences in values and worries about treatment may explain why.
Methods—Women with OC in 2013–2015 were surveyed about values and worries at the time of 
initial treatment. Existing values (11 item, e.g., maintaining quality of life) and worries (12 items, 
e.g., treatment side effects) scales were adapted based on OC literature. Responses were very/
somewhat/a little/not at all important or worried. Principal Component Analyses (PCA) identified 
groups of values and worries that best explained scales' variation. We examined proportions 
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reporting very/somewhat important/worried on ≥1 item in each component by age (older ≥65 
years, younger <65 years).
Results—Of 170 respondents, 42.3%were older. PCA components for values were: functional 
well-being (3 survey items, proportion of variance explained [PoVE] 26.3%), length of life and 
sexual functioning (3 items, PoVE 20.1%), attitudes (3 items, PoVE 14.2%), and not becoming a 
burden (2 items, PoVE 13.7%). PCA components for worries were: economic (4 items, PoVE 
27.2%), uncertainty (6 items, PoVE 26.0%), and family impact (2 items, PoVE 16.3%). Older 
women were less likely to indicate very/somewhat worried to ≥1 item in the economic (51.4% vs 
72.4%, p = 0.006), uncertainty (80.6% vs. 98.0%, p = 0.001), and family impact component 
(55.6% vs. 70.4%, p = 0.03). No other age differences were found.
Conclusions—While worry during OC treatment decision-making may differ across age groups, 
values do not. Research should assess how differences in worry might affect OC medical decision-
making for older and younger women.
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1. Introduction
Approximately 20,000 women are diagnosed with ovarian cancer annually, the deadliest 
gynecologic cancer with a five-year survival rate of 46% [1]. The age group of women 65 
years old and older is particularly vulnerable to this cancer: incidence rates are 6 times and 
mortality rates are 13 times higher in the older population than in women younger than 65 
[1]. The advances in treatment have improved the prognosis for ovarian cancer; however, not 
all women diagnosed with this disease, in particular older women, receive care congruent 
with current evidence-based guidelines, including the National Comprehensive Cancer 
Network (NCCN) guidelines [1–4].
Advanced age is a predictor of guideline incongruent care with older women being less 
likely to receive guideline directed treatment or receive care from specialists, i.e., 
gynecologic oncologists [1]. While various reasons may contribute to this disparity, one 
reason may be related to different treatment goals [5]. Values such as the desire to prolong 
life may be different across the age spectrum, with older adults being more sensitive to the 
effects of treatment on functionality and other impairments [6–8]. Moreover, considerations 
related to child-bearing, maintaining high sexual function, family, work and costs may also 
differ by age. Worrying about economic consequences of cancer is not uncommon: among 
lung and colorectal cancer patients, as many as 40% worry about the cost of treatment and 
more than half about time away from work [9]. Given the insurance coverage through 
Medicare, however, women who are 65 years old or older may differ in how they value or 
worry about costs of care. Understanding preferences and values, as well as worries at the 
time of treatment decisions, is fundamental not only to understand differences in patterns of 
care, but also to achieve the Institute of Medicine's vision of patient-centered care that is 
consistent with patients' values, needs, and preferences [1].
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Currently, we know little about what women with ovarian cancer value or worry about at the 
time of treatment, and whether younger and older women differ in their evaluation of these 
factors. We begin to address this knowledge gap with a survey of 170 women who received 
ovarian cancer treatment in Alabama and Georgia. We aimed at identifying which values and 
worries were most prominent using Principal Component Analysis (PCA). Moreover, given 
differences that may exist by age, we examine values and worries for women who were 
younger vs. older than 65 years.
2. Methods
The Research to Understand Treatment Choices in Ovarian Cancer (RUTH) study aimed to 
understand the factors that women and their physicians consider when making decisions 
about ovarian cancer treatment. The RUTH study was approved by the University of 
Alabama at Birmingham Institutional Review Board.
2.1. Survey development
The survey collected information on demographics, symptoms leading to diagnosis, initial 
treatment offered and received, medical decision making, goals of treatment and prognosis, 
and other financial/coverage-related information. The survey instrument was adapted from 
the questionnaire used for the Cancer Care Outcomes Research and Surveillance Consortium 
(CanCORS) (http://appliedresearch.cancer.gov/cancors/), which surveyed lung and 
colorectal cancer patients to examine patient- reported outcomes and clinical and 
psychosocial domains pertaining to medical decision-making [10]. Questions most relevant 
to the intent of the survey were retained from CanCORS including questions on what 
patients worried about at the time of treatment. Other CanCORS questions retained were 
about the beliefs and barriers to doctors and specific treatments, satisfaction with care, and 
support.
We added questions to the survey instrument on the values that were important to women at 
the time of treatment, adapting them from literature on medical decision making and directly 
related to ovarian cancer. Specifically, we adapted questions related to fertility sparing 
surgery or sexual concerns, which have been shown to be important domains for women 
with OC [11–13].
The survey was piloted in two rounds with five ovarian cancer patients identified through the 
University of Alabama at Birmingham's healthcare system, and cancer survivors from an 
ovarian cancer support group in Birmingham, AL. The development of survey questions was 
informed by these discussions and the survey was modified accordingly.
2.2. Patient population and recruitment
RUTH participants were recruited from several different sources: 1) the University of 
Alabama at Birmingham (UAB) hospital (45.3%); 2) the University of South Alabama/
Mitchell Cancer Institute (MCI) in Mobile, AL, (20.6%) and Northside Hospital in Atlanta, 
GA (19.4%); and 3) the Alabama Statewide Cancer Registry (ASCR) (14.7%) (Table 1). 
Eligible patients included women who 1) were age 21 years or older; 2) had a recent 
diagnosis of ovarian cancer (diagnosis within two years with stage I–IV, as defined by the 
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International Federation of Gynecology and Obstetrics (FIGO) or unstaged ovarian cancer); 
3) were proficient in the English language and able/willing to provide their consent to 
participate in the telephone-based survey. Women were excluded if they were currently 
being treated for another primary cancer or were institutionalized (including hospice). We 
documented reasons for non-participation (e.g. disconnected phone/could not be reached, 
non-English speaker, etc.), or personal preference in declining participation.
Survey recruitment strategies had minor variations by site. At UAB and MCI, potential 
participants were initially contacted with a letter from the gynecologic oncology division 
that provided detailed information about the study and the option to decline participation by 
dialing a 1–800 phone number or by email. At Northside Hospital, a research nurse 
contacted potential participants to assess interest. The ASCR sought physicians' consent to 
contact patients before releasing the contact list to RUTH investigators. After receiving the 
information letter, all potential participants were then contacted by recruiters of the UAB 
Recruitment and Retention Shared Facility (RRSF). RRSF recruiters administered the 
eligibility screen, obtained verbal consent, and scheduled a date/time for the 60-minute 
structured, phone-based interview. Calls were placed at different days/times across the week 
and weekend, with a maximum of 7 attempts. Participants who refused to participate in the 
interview were coded as “final refusal” and were not contacted again.
2.3. Survey administration
All surveys were administered by the UAB Survey Research Unit (SRU) of the Center for 
the Study of Community Health over the 2013–2015 period. The SRU interviewers were 
professionally trained on proper interviewing techniques, unbiased probing, questions/skip 
patterns and using the Computerized Assisted Telephone Interview (CATI) system. Each 
interviewer received study-specific training to assure familiarity with the content. As a 
quality assurance measure, interviewers were randomly, electronically monitored, at 
minimum four times per month. Interviews were recorded through the CATI system and data 
were maintained in a secure format. All participants received a $50.00 gift card for 
completing the survey.
2.4. Study outcomes
The main outcomes for this analysis are the values and worries expressed by RUTH 
participants. Respondents were asked to indicate what was important to them at the time 
they discussed initial treatment with the doctor. Respondents could indicate very, somewhat, 
a little, or not at all important on 11 value items. Similarly, respondents were asked how 
much they were worried about 12 worry items at the time they were making decisions about 
their ovarian cancer treatment. Respondents would indicate very, somewhat, a little, or not at 
all worried.
2.5. Analysis
Frequencies, means, and standard deviations were calculated for categorical and continuous 
variables, respectively. Demographic and clinical variables were stratified by age. Chi-
square tests were used to test for significance of differences between those <65 years of age 
and those 65+ at the time of the survey.
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The frequency of reporting that a value was “very” or “somewhat” important for each of the 
11 value items, and the frequency of reporting “very” or “somewhat” worried for each of the 
12 worry items, were calculated overall and by age groups. Logistic regression analysis, 
adjusting for stage and work status, were used to evaluate the differences between those <65 
vs. 65+.
2.5.1. Principal Components Analysis (PCA)—We conducted PCA to identify the 
most prominent values and worries, and how they group together in overall themes. PCA is a 
multivariate statistical technique used to reduce the number of variables in a data set into a 
smaller number of ‘components’, or groupings of variables [14,15]. Essentially, PCA 
provides a method to identify different dimensions existing within a set of correlated 
variables. In our study, we used PCA to determine the primary components of the 11 item 
values scale and the 12 item worry scale.
Each of the components from PCA are linear weighted combinations of the initial scale 
items. The weights for each component are determined by eigenvectors (factors) of the 
correlation matrix. The components are ordered so that the first component explains the 
largest possible amount of variation in the original data. Subsequent components explain 
additional variation, but less variation than the first component. The proportion of the total 
variation in the original data set accounted by each principal component is determined by the 
variance of the individual component divided by the total number of items. Each component 
is representative of an additional dimension in the data, while explaining smaller and smaller 
proportions of the variation of the original variables. The higher the degree of correlation 
among the original variables in the data, the fewer components required to capture common 
information.
We dichotomized each item in the set of questions about values to “somewhat/very 
important” and “not important at all/not very important”; for the worry scale, we 
dichotomized the 12 items as “worried” and “not worried/a little worried.” We used a 
tetrachoric correlation matrix for each of the PCAs to account for the dichotomous nature of 
the data. To identify the simplest data structure, we used an unrotated and a varimax rotation 
(orthogonal rotation, assumes no correlation among components). To identify the relevant 
number of components in each of the value and worry scales, we conducted the PCA 
without pre-specifying the number of components. Scree plots and eigenvalues (>1) were 
evaluated to determine the appropriate number of components for each scale. Each 
component is comprised of items with factor loadings (e.g., correlations to the component) 
of ≥0.40.
We then calculated the proportion by age group of respondents who indicated “very” or 
“somewhat” important to at least one item in the value components, and the proportion of 
respondents by age group who indicated “very” or “somewhat” worried to at least one item 
in the worry components. We then tested for significant differences in these proportion by 
age group using logistic regressions adjusted for stage and work status.
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3. Results
3.1. Population characteristics
One hundred and seventy women participated in the RUTH survey. The response rate among 
the women who could be reached was 66%. The mean age of the women was 61.8 (standard 
deviation 11.6) years; 42.3% were 65 years or older at the time of the survey, 24.1% African 
American, 38.2% with high school education or less, and 58.2% retired (Table 1). Most 
(82.6%) were within 18 months of the ovarian cancer diagnosis, 22.5% were diagnosed with 
FIGO stage I–II disease, 46.7% with stage III–IV, and the rest were not staged or the stage 
was missing. Women 65 and older at the time of the survey were similar to younger women 
except for being more likely to be retired (p < 0.0001) and, although not significant at a 5% 
level, more likely to have stage III–IV disease (p = 0.06).
3.2. Values
Overall, for >90% of survey participants, “maintaining a positive attitude,” “not becoming a 
burden to the family,” “living as long as possible,” and “maintaining quality of life,” were 
each “very important” values (Table 2). These values were supported by both younger and 
older women; older women endorsed “living as long as possible” as a “very” important 
value less frequently (87.5% vs 95.9%, adjusted p = 0.04 adjusted for stage and work status) 
than younger women. About 66 to 82% of women reported “maintaining the ability to do 
activities they enjoy”, “returning to work or other routine activities,” or “not sacrificing 
plans for the family” as “very” or “somewhat” important values (Table 2). Moreover, about 
one-third of women reported as “very” or “somewhat” important having “doctors who 
shared their religious beliefs,” while about 25% reported as “very” or “somewhat” important 
“maintaining a satisfying sexual life.” Older women were less often indicated that 
maintaining a satisfying sexual life was “very” or “somewhat” important (combined 
“very”/”somewhat” important responses: 30.6% vs 59.1%, adjusted p = 0.001).
3.3. Worries
Overall, about one-third of women (between 31.2 and 37.6%) indicated being “very 
worried” about “developing cancers later,” “not knowing what to expect,” “the side effects 
from treatment,” and “being financially set back because of medical expenses” (Table 2). 
For these items, older women were significantly less likely to indicate being “very” or 
“somewhat” worried about developing cancer later (combined “very”/“somewhat” worried: 
61.1% vs. 78.5%, adjusted p = 0.007), not knowing what to expect (“very”/“somewhat” 
worried: 57.0% vs 74.5%, p = 0.01), and being financially set back by treatment costs 
(“very”/“somewhat” worried: 40.3% vs. 63.3%, adjusted p = 0.046). Older women were less 
likely to be “very” worried about the side effects from treatment (23.6% vs. 38.8%, adjusted 
p = 0.03). Overall, >24% indicated being “very” worried about “taking time away from the 
family,” the “cost of treatment” and “using all their savings or retirement funds to pay for 
their care.” Older women were less likely to be “very” or “somewhat” worried about the 
“cost of treatment” (“very”/“somewhat” worried 40.3% vs. 60.2%, adjusted p = 0.01) and 
“taking time away from work or other daily activities” (“very”/“somewhat” worried 41.7% 
vs. 63.2%, adjusted p = 0.02). Overall, <13% of respondents were “very” worried about 
changes in body image, having to post-pone medical care for the family, transportation, or 
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going through early menopause. Older women were less likely to be “very” or “somewhat” 
worried about changes in body image (“very”/“somewhat” worried 25.0% vs 42.8%, p = 
0.03) and going through early menopause (“very”/“somewhat” worried 2.8% vs. 19.4%, p = 
0.009) (Table 2).
3.4. Principal Components Analysis (PCA) results
3.4.1. Values scale—PCA results indicate up to four components were present among the 
11 value questions. The first included 3 items related to functional well-being and explained 
26.3% of total variance in the values scale (Table 3). The second component included 3 
items on maintaining length of life and sexual functioning and explained 20.1% of the total 
variance. The third component included 3 items related to attitudes and explained 14.2% of 
the overall variance. The fourth component included two items related to not becoming a 
burden to the family and explained 13.7% of the variance. The proportion of respondents 
indicating “very” or “somewhat” important to at least one item within each value component 
was >98.6% for all factors with no difference by age group (data not shown).
3.4.2. Worries Scale—PCA results indicate up to three components were present among 
the 12 worry questions (Table 4). The first component included 4 items related to cost or 
economic worry and explained 27.2% of the total variance in the worry scale. The second 
included 6 items on the physical consequences and uncertainty imposed by the disease and 
explained 26% of the total variance. The third component included 3 items related to the 
effect of cancer on the family and explained 16.3% of the overall variance. The proportion of 
respondents indicating “very” or “somewhat” worried to at least one item within each worry 
component was 63.5% for factor 1, 90.6% for factor 2, and 64.1% for factor 3. Older women 
were less likely to indicate “very” or “somewhat” worried to at least one item of each worry 
component of economic concerns (51.4% vs 72.4%, p = 0.006), uncertainty (80.6% vs. 
98.0%, p = 0.001), and cancer impact (55.6% vs. 70.4%, p = 0.03).
4. Discussion
In this sample of 170 women diagnosed with ovarian cancer, we identified the values and the 
worries that were important when making decisions about treatment. Women valued various 
factors in addition to prolonging life: in fact, almost all women, regardless of age, endorsed 
as “very important” values related to maintaining “your quality of life” and “the ability to do 
the activities you enjoy,” “a positive attitude,” and “not become a burden to your 
family.”Worries were not only about side effects of treatment or cancer recurrence: at least 
one out of three women were very worried about the uncertainty associated with cancer, not 
only as it related to physical consequences, but also as it related to economic stability. 
Although less than younger women, a significant proportion of older women worried about 
the consequences of cancer. However, it is unclear how our findings might explain the 
observed differences in treatment observed by others for younger and older women with 
ovarian cancer [1].
Understanding values and worries at the time of treatment decision making is important to 
allow for the best process and the best patient-centered care. It is unclear how the values and 
worries of cancer patients are incorporated in decision-making. In one small qualitative 
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study, only a few women with ovarian cancer reported having discussions regarding goals of 
treatment and values before treatment decisions were made [16]. In this same study, women 
emphasized their interest in discussing quality of life rather than progression free and overall 
survival [16]. This is supported by our findings that women clearly endorsed the importance 
of maintaining both quality and length of life, while not becoming a burden for the family. 
These values need to be considered carefully when making treatment choices, and women 
need to be encouraged to express these values in their own context. There is less information 
in the literature on what cancer patients worry about. Our respondents reported a high level 
of worry about several factors related to treatment decisions, a level that may be higher than 
in patients of other cancers. Among lung and colorectal cancer patients, three quarters were 
worried about treatment side effects when making decisions about cancer treatment, but a 
substantial proportion were also worried about time away from the family (50%), cost of 
treatment (40%), time away from work (52%), and transportation to treatment (22%) [9]. In 
our group of ovarian cancer patients, if “worried” was defined as in Martin et al. [9], (i.e., 
any respondent who reported at least some level of worry) we would find that 87.7% 
reported being worried about side effects, 78.8% about time away from family, 67.6% about 
cost of treatment, 73.5% about taking time from work, and 27.1% about transportation. 
These proportions are considerably higher than in Martin et al.. However, study populations 
are not closely comparable: Martin et al. included men and women with lung and colorectal 
cancer diagnoses of whom nearly half had early stage disease (stages I and II). Early stage 
may be when treatment decision-making can be influenced differently [9]. Further research 
should examine whether the extent of worry differs, and how worries may impact treatment 
decisions, across cancer types and stage. Overall, however, our finding that one in three 
women diagnosed with ovarian cancer were very worried about several factors is notable and 
needs to be addressed.
We did not find differences in values by age group. Our results are in line with others who 
have found that cancer patients, including older ones, highly value maintaining their quality 
of life and ability to do the activities they enjoy, as well as not becoming a burden to their 
families [6–8]. Our study adds to this literature findings on differences by age in what 
women worry about. In general, older women were less likely to report being very worried 
about all items we inquired about. About one in five were very worried about developing 
other cancers, the uncertainty that cancer brings, the side effects, and the financial 
consequences, compared to more than one in three younger women. Therefore, difference in 
worries about cancer, its treatment and its consequences, may not be enough to understand 
differences in treatment across age groups. It would be important to test in future research 
efforts whether women who have high level of worry are indeed more likely to forgo or 
delay cancer treatment or seek care from specialists, and to identify groups of women who 
may be more likely to worry, for example those with lower incomes or with multiple 
comorbid conditions. Additionally, whether the level of worry that influences treatment 
decisions differs by age is another important area of research that can provide insight into 
understanding differences in cancer treatment.
It is worth highlighting that concerns about costs of care and the financial implications of 
cancer treatment were very important for our respondents: the variance explained by these 
worry factors in the principal component analysis (in the three-factor solution) was the 
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highest for the worry questionnaire. More than a quarter were very worried about the cost of 
treatment, and more than two thirds (67.6%) worried a little; the latter is considerably higher 
than the 40% of colorectal and lung cancer patients who worried about costs in Martin et al. 
[9]. This may be due to several factors among which the high cost of treatment for ovarian 
cancer. Among young and older women, this cancer was found to be costlier than lung and 
colorectal cancer [17]. In addition, we surveyed women between 2013 and 2015, while the 
colorectal and lung cancer patients in Martin et al. were surveyed between 2003 and 2005, 
and thus before the economic recession of the late 2000s. Moreover, the women we surveyed 
were mainly from Alabama, one of the poorest states in the US: these women may be more 
concerned about their economic constraints overall. Regardless of the reasons, it is 
significant that two out of three women worried about the costs of cancer care and that 
economic issues were the main components of what they worried about. This is in line with 
current literature that calls attention to financial and economic implications as another side 
effect of cancer treatment [18–21]. The implications these may have for the well-being of 
women with ovarian cancer, and how to address them, needs to be investigated. Breast 
cancer survivors, for example, suggested that knowing the costs of care upfront would help 
in dealing with financial challenges [22]. Similar interventions may also help women with 
ovarian cancer.
This study has some limitations to be considered. First, participants were recruited from 
three hospitals in two southern states and the Alabama Statewide Cancer Registry; they may 
not, thus, represent all women with ovarian cancer in the US or in the Southeast. Second, 
women received treatment mainly at large cancer centers and may not represent women who 
receive care at other smaller centers. Third, the sample size is relatively small and does not 
allow us to conduct separate PCA by age group to assess the difference in principal 
components by age group. Fourth, the sample included women who survived ≥18 months 
after diagnosis. Given that patients were asked to recall back to the time of treatment 
decision-making, there is potential for recall bias captured in these responses.
In conclusion, our paper contributes to the understanding of values and concerns of cancer 
patients, in particular filling a knowledge gap about those of women with ovarian cancer 
across different age groups. We believe these are important considerations to assure 
treatment that is patient-centered and reflective of preferences of patients of all ages. While 
values were comparable for women across all ages, older women reported being less worried 
about the consequences of ovarian cancer. Further research is needed to assess how these 
worries and values affect the medical decision making for patients with ovarian cancer, and 
whether differences by age may or may not contribute to the observed differences in 
treatment for older women and younger women [1].
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HIGHLIGHTS
• Values of ovarian cancer patients regarding treatment do not vary by age.
• Overall, women value functional well-being, life length and sexual function
• Women also value positive attitudes and not becoming a burden.
• Although a majority do, older women are less likely to report worries than 
younger ones.
• Worries are related to uncertainty, and economic and family impact.
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Table 1
Demographic and clinical characteristics of women with ovarian cancer who participated in RUTH.
Characteristic All
(n = 170) Age
b
<65
(n = 98)
Ageb
65+
(n = 72)
Chi-squarec
% % % P
Age 24–55 25.9 – –
Age 55–64 31.8 – –
Age 65–90 42.3 – –
Race 0.39
  White 72.3 69.4 76.4
  African American 24.1 26.5 20.8
  Otherd 3.5 4.1 2.8
Education 0.34
  High school or less 38.2 37.8 38.9
  Some college/Tech degree 37.1 33.7 41.7
  College or more 24.7 28.6 19.4
Employment status <0.0001
  Retired or disabled 58.2 42.9 79.2
  Employed 24.7 31.6 15.3
  Other 17.1 25.5 5.6
Time since diagnosis >18 months 17.4 15.8 19.4 0.30
Stage 0.06
  I – II 22.5 26.8 16.7
  III–IV 46.7 39.2 56.9
  Not staged or stage missing 30.8 34.0 26.4
Number of comorbidities 0.20
  None 16.5 21.4 9.7
  1–2 58.2 53.1 65.3
  3+ 25.3 25.5 25.0
Study sitea 0.66
  UAB 45.3 48.0 41.7
  MCI 20.6 21.4 19.4
  Northside Hospital 19.4 16.3 23.6
  ASCR 14.7 14.3 15.3
aUAB: University of Alabama at Birmingham, MCI: Mitchell Cancer Institute, ASCR: Alabama State Cancer registry.
bAge ranged from 24 years to 90 years; mean age of the women was 61.8 (standard deviation 11.6).
cChi-square test for the difference by age group.
dOther race included: Hispanic, Asian and non-specified “Other race.”
Gynecol Oncol. Author manuscript; available in PMC 2018 March 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Pisu et al. Page 14
Ta
bl
e 
2
Va
lu
es
 im
po
rta
nt
 to
 w
o
m
en
, 
an
d 
w
ha
t t
he
y 
w
o
rr
ie
d 
ab
ou
t, 
w
he
n 
th
ey
 d
isc
us
se
d 
tre
at
m
en
t w
ith
 th
ei
r d
oc
to
rs
, a
nd
 d
iff
er
en
ce
s b
y 
ag
e 
at
 th
e 
tim
e 
of
 su
rv
ey
.
A
ll 
w
o
m
en
A
ge
 <
 6
5
A
ge
 6
5+
%
 re
po
rti
ng
 v
er
y 
or
 so
m
ew
ha
t i
m
po
rta
nt
H
ow
 im
po
rta
nt
 w
as
 it
 fo
r y
ou
 to
:
Ve
ry
So
m
ew
ha
t
Ve
ry
So
m
ew
ha
t
Ve
ry
So
m
ew
ha
t
 
 
M
ai
nt
ai
n 
a 
po
sit
iv
e 
at
tit
ud
e
96
.5
2.
3
95
.9
3.
1
97
.2
1.
4
 
 
N
ot
 b
ec
om
e 
a 
bu
rd
en
 to
 y
ou
r f
am
ily
94
.7
1.
8
96
.9
1.
0
91
.7
2.
8
 
 
Li
v
e 
as
 lo
ng
 a
s p
os
sib
le
a
92
.3
5.
3
95
.9
3.
1
87
.5
8.
3
 
 
M
ai
nt
ai
n 
yo
ur
 q
ua
lit
y 
of
 li
fe
91
.8
5.
3
92
.9
6.
1
90
.3
4.
2
 
 
M
ai
nt
ai
n 
th
e 
ab
ili
ty
 to
 d
o 
th
e 
ac
tiv
iti
es
 y
ou
 e
njo
y
82
.3
11
.2
83
.7
11
.2
80
.6
11
.1
 
 
R
et
ur
n 
to
 w
o
rk
 o
r u
su
al
 a
ct
iv
iti
es
70
.6
15
.3
73
.5
15
.3
66
.7
16
.7
 
 
N
ot
 to
 sa
cr
ifi
ce
 p
la
ns
 y
ou
 h
ad
 fo
r y
ou
r f
am
ily
65
.9
22
.9
69
.4
20
.4
61
.1
26
.4
 
 
H
av
e 
do
ct
or
s w
ho
 sh
ar
ed
 y
ou
r r
el
ig
io
us
 b
el
ie
fs
31
.8
31
.8
30
.6
30
.6
33
.3
33
.3
 
 
M
ai
nt
ai
n 
a 
sa
tis
fy
in
g 
se
x
u
al
 li
fe
a,
b
24
.7
22
.3
32
.6
26
.5
13
.9
16
.7
 
 
K
ee
p 
yo
ur
 a
bi
lit
y 
to
 h
av
e 
ch
ild
re
n
5.
9
1.
2
6.
1
2.
0
5.
6
0.
0
 
 
K
ee
p 
yo
ur
 u
te
ru
s
2.
9
3.
5
4.
1
4.
1
1.
4
2.
8
%
 re
po
rti
ng
 b
ei
ng
 v
er
y 
or
 so
m
ew
ha
t w
o
rr
ie
d
H
ow
 m
u
ch
 w
er
e 
yo
u 
w
o
rr
ie
d 
ab
ou
t…
Ve
ry
So
m
ew
ha
t
Ve
ry
So
m
ew
ha
t
Ve
ry
So
m
ew
ha
t
 
 
D
ev
el
op
in
g 
ot
he
r c
an
ce
rs
 la
te
rc
,
d
37
.6
33
.5
46
.9
31
.6
25
.0
36
.1
 
 
N
ot
 k
no
w
in
g 
w
ha
t t
o 
ex
pe
ct
d
37
.1
30
.0
42
.9
31
.6
29
.2
27
.8
 
 
Th
e 
sid
e-
ef
fe
ct
s f
ro
m
 tr
ea
tm
en
tc
32
.3
35
.9
38
.8
32
.6
23
.6
40
.3
 
 
B
ei
ng
 se
t f
in
an
ci
al
ly
 b
ac
k 
be
ca
us
e 
of
 m
ed
ic
al
 ex
pe
ns
es
c,
d
31
.2
22
.3
37
.8
25
.5
22
.2
18
.1
 
 
Ta
ki
ng
 ti
m
e 
aw
ay
 fr
om
 y
ou
r f
am
ily
29
.4
32
.3
34
.7
32
.6
22
.2
31
.9
 
 
Th
e 
co
st 
of
 tr
ea
tm
en
tc
,
d
28
.2
23
.5
37
.8
22
.4
15
.3
25
.0
 
 
U
sin
g 
up
 sa
v
in
gs
 o
r r
et
ire
m
en
t f
un
ds
 to
 p
ay
 fo
r c
an
ce
r c
ar
e
27
.1
17
.1
30
.6
18
.4
22
.2
15
.3
 
 
Ta
ki
ng
 ti
m
e 
aw
ay
 fr
om
 w
o
rk
 o
r o
th
er
 d
ai
ly
 a
ct
iv
iti
es
c,
d
24
.1
30
.0
32
.6
30
.6
12
.5
29
.2
 
 
Ch
an
ge
s i
n 
bo
dy
 im
ag
ed
12
.9
22
.3
17
.3
25
.5
6.
9
18
.1
 
 
H
av
in
g 
to
 p
os
tp
on
e/
av
o
id
 m
ed
ic
al
 c
ar
e 
fo
r f
am
ily
10
.0
12
.9
12
.2
14
.3
6.
9
11
.1
 
 
Tr
an
sp
or
ta
tio
n 
to
 tr
ea
tm
en
t
9.
4
9.
4
11
.2
12
.2
6.
9
5.
6
 
 
G
oi
ng
 th
ro
ug
h 
ea
rly
 m
en
op
au
se
d
5.
3
7.
1
8.
2
11
.2
1.
4
1.
4
Gynecol Oncol. Author manuscript; available in PMC 2018 March 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Pisu et al. Page 15
a S
ta
tis
tic
al
ly
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 p
ro
po
rti
on
s r
ep
or
tin
g 
v
er
y 
im
po
rta
nt
 b
y 
ag
e 
(p 
<
 0
.0
5).
 L
og
ist
ic 
reg
re
ss
io
ns
 a
dju
ste
d f
or 
sta
ge
 an
d w
o
rk
 st
at
us
.
b S
ta
tis
tic
al
ly
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 p
ro
po
rti
on
s r
ep
or
tin
g 
v
er
y 
or
 so
m
ew
ha
t i
m
po
rta
nt
 b
y 
ag
e 
(p 
<
 0
.0
5).
 L
og
ist
ic 
reg
re
ss
io
ns
 a
dju
ste
d f
or 
sta
ge
 an
d w
o
rk
 st
at
us
.
c S
ta
tis
tic
al
ly
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 p
ro
po
rti
on
s r
ep
or
tin
g 
v
er
y 
w
o
rr
ie
d 
by
 a
ge
 (p
 
<
 0
.0
5).
 L
og
ist
ic 
reg
re
ss
io
ns
 a
dju
ste
d f
or 
sta
ge
 an
d w
o
rk
 st
at
us
.
d S
ta
tis
tic
al
ly
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 p
ro
po
rti
on
s r
ep
or
tin
g 
v
er
y 
or
 so
m
ew
ha
t w
o
rr
ie
d 
by
 a
ge
 (p
 
<
 0
.0
5).
 L
og
ist
ic 
reg
re
ss
io
ns
 a
dju
ste
d f
or 
sta
ge
 an
d w
o
rk
 st
at
us
.
Gynecol Oncol. Author manuscript; available in PMC 2018 March 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Pisu et al. Page 16
Ta
bl
e 
3
Pr
in
ci
pa
l C
om
po
ne
nt
s A
na
ly
sis
 re
su
lts
 fo
r t
he
 q
ue
sti
on
s o
n 
va
lu
es
: f
ac
to
r l
oa
di
ng
s a
nd
 v
ar
ia
nc
e 
ex
pl
ai
ne
d.
a
Va
lu
es
C
om
po
ne
nt
s
1
2
3
4
M
ai
nt
ai
n 
th
e 
ab
ili
ty
 to
 d
o 
th
e 
ac
tiv
iti
es
 y
ou
 e
njo
y
0.
91
70
6
−
 
0.
21
84
5
0.
01
71
6
0.
13
01
8
M
ai
nt
ai
n 
yo
ur
 q
ua
lit
y 
of
 li
fe
0.
82
53
4
0.
01
27
7
0.
19
62
1
−
 
0.
02
15
3
R
et
ur
n 
to
 w
o
rk
 o
r u
su
al
 a
ct
iv
iti
es
0.
81
16
8
−
 
0.
20
44
4
0.
10
72
3
0.
10
84
6
Li
v
e 
as
 lo
ng
 a
s p
os
sib
le
−
 
0.
25
61
4
0.
92
49
6
0.
00
70
9
−
 
0.
00
89
4
M
ai
nt
ai
n 
a 
sa
tis
fy
in
g 
se
x
u
al
 li
fe
−
 
0.
19
49
4
0.
87
98
6
−
 
0.
16
64
3
−
 
0.
06
64
5
K
ee
p 
yo
ur
 u
te
ru
s
0.
53
37
9
0.
59
94
3
−
 
0.
01
04
1
0.
16
06
9
K
ee
p 
yo
ur
 a
bi
lit
y 
to
 h
av
e 
ch
ild
re
n
0.
33
20
9
0.
11
97
7
0.
75
41
9
−
 
0.
14
81
2
H
av
e 
do
ct
or
s w
ho
 sh
ar
ed
 y
ou
r r
el
ig
io
us
 b
el
ie
fs
−
 
0.
14
01
2
−
 
0.
32
73
6
0.
75
02
6
0.
23
15
1
M
ai
nt
ai
n 
a 
po
sit
iv
e 
at
tit
ud
e
0.
28
01
5
−
 
0.
07
52
2
0.
56
83
6
0.
52
84
3
N
ot
 b
ec
om
e 
a 
bu
rd
en
 to
 y
ou
r f
am
ily
0.
32
36
3
−
 
0.
07
05
2
−
 
0.
09
64
7
0.
75
39
9
N
ot
 to
 sa
cr
ifi
ce
 p
la
ns
 y
ou
 h
ad
 fo
r y
ou
r f
am
ily
−
 
0.
12
38
8
0.
07
00
0
0.
14
40
7
0.
72
52
4
Va
ria
nc
e 
ex
pl
ai
ne
d 
by
 e
ac
h 
co
m
po
ne
nt
2.
89
80
3
2.
21
57
2
1.
56
29
4
1.
50
87
5
Pe
rc
en
t o
f t
ot
al
 v
ar
ia
nc
e 
ex
pl
ai
ne
d 
by
 c
om
po
ne
nt
 (v
ar
ia
nc
e 
/ n
um
be
r o
f i
te
m
s)
26
.3
%
20
.1
%
14
.2
%
13
.7
%
In
di
ca
te
d 
in
 b
ol
d 
ar
e 
fa
ct
or
 lo
ad
in
gs
 o
f i
te
m
s t
ha
t d
ef
in
e 
a 
co
m
po
ne
nt
.
a R
ot
at
ed
 fa
ct
or
 lo
ad
in
g;
 T
et
ra
ch
or
ic
 c
or
re
la
tio
n 
m
at
rix
; v
ar
im
ax
 (o
rth
og
on
al)
 ro
tat
ion
.
Gynecol Oncol. Author manuscript; available in PMC 2018 March 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Pisu et al. Page 17
Table 4
Principal Components Analysis results for the questions on worries: factor loadings and variance explained.a
Worries Component
1 2 3
  Using up savings or retirement funds to pay for cancer care 0.88115 0.17152 0.23364
  The cost of treatment 0.84507 0.27797 0.21274
  Being set financially back because of medical expenses 0.83082 0.29038 0.36563
  Transportation to treatment 0.66637 0.38224 0.00403
  The side-effects from treatment 0.27847 0.80405 − 0.14110
  Going through early menopause 0.08647 0.68381 0.29595
  Not knowing what to expect 0.32925 0.68363 0.29778
  Changes in body image 0.26301 0.60818 0.23418
  Taking time away from work or other daily activities 0.30516 0.57993 0.44538
  Developing other cancers later 0.42510 0.57513 0.23232
  Having to postpone or avoid medical care for other family members 0.28372 0.05902 0.81380
  Taking time away from your family 0.12975 0.39884 0.74237
Variance explained by each factor 3.25864 3.11807 1.95028
Percent of total variance explained by component (variance / number of items) 27.2% 26.0% 16.3%
Indicated in bold are factor loadings of items that define a component.
a
Rotated factor loading; Tetrachoric correlation matrix; varimax (orthogonal) rotation.
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